MAPT and Alzheimer disease: Apart from tau biomarkers in the CSF and PET, plasma phosphorylated tau at threonine 181 (p-tau181) is a validated AD-specific biomarker, demonstrating significant sensitivity for the prediction of incident cognitive decline (38–40).